title: CD30-positive cutaneous T-cell lymphoma and response to Brentuximab Vedotin: 2 illustrative cases.
authors: Hematology and Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA. frederick.lansigan@hitchcock.org
authors: Kabir
authors: K
authors: Mody
authors: Jill S
authors: JS
authors: Wallace
authors: Diane M
authors: DM
authors: Stearns
authors: George
authors: G
authors: Bowers
authors: Shannon R
authors: SR
authors: Lacy
authors: Norman B
authors: NB
authors: Levy
authors: Kathryn A
authors: KA
authors: Zug
authors: Frederick
authors: F
authors: Lansigan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000079963:Brentuximab Vedotin; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000276:immunology*; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000276:immunology*; D008297:Male
chemical_list: D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin